Crucell agreement gives Upstate use of PER.C6 cell line

By Lisa Kerner

Erie, Pa., May 16 - Dutch biotechnology company Crucell NV signed a PER.C6 licensing agreement with Upstate USA, Inc., a wholly owned subsidiary of Virginia-based Serologicals Corp.

The non-exclusive agreement allows Upstate to use the PER.C6 cell line to propagate adenovirus containing siRNA that will be sold to the biomedical community for research purposes, according to a company news release.

Under the agreement, Upstate will pay a license issuance fee, annual maintenance fees and a royalty to Crucell. Additional financial details were not disclosed.

Galapagos BV, Crucell's exclusive PER.C6 licensee in the field of functional genomics, will supply the siRNA to Upstate.

Based in Leiden, The Netherlands, Crucell is a biotechnology company focused on research, development and marketing of vaccines and antibodies that prevent and treat infectious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.